CN108531606A - Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 - Google Patents
Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 Download PDFInfo
- Publication number
- CN108531606A CN108531606A CN201810742140.4A CN201810742140A CN108531606A CN 108531606 A CN108531606 A CN 108531606A CN 201810742140 A CN201810742140 A CN 201810742140A CN 108531606 A CN108531606 A CN 108531606A
- Authority
- CN
- China
- Prior art keywords
- ifng
- rna
- coding rna
- kidney
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of application, kit and the detection methods of kidney prognosis novel molecular marker non-coding RNA IFNG AS1, it is related with the survival rate of patient by real-time fluorescence quantitative PCR and the survivorship curve analysis non-coding RNA IFNG AS1 for finding renal carcinoma tissue source, content is higher, survival rate is higher, this method provides strong technical support to predict that the prognosis life cycle of patients with renal cell carcinoma is analyzed, help to improve the postoperative life quality of patients with renal cell carcinoma, work out aftertreatment scheme, survival rate is improved, there is far-reaching clinical meaning.
Description
Technical field
The invention belongs to oncomolecularbiology fields, and in particular to a kind of kidney prognosis novel molecular marker non-coding
Application, kit and the detection method of RNA IFNG-AS1.
Background technology
Kidney, also known as clear-cell carcinoma, incidence account for the 3% of whole body malignant tumour, are shown as pathologically 75% transparent
The kidney of cell cancer, different pathological types has different clinical characters, therapeutic scheme and prognosis.Blood urine, pain, lump are known as
Three signs of kidney.It is asymptomatic patient serendipitous clinically to have 40% or so case, and has symptom big in diagnosis
All has or will occur metastasis.The primary treatments of kidney are surgical operation radical cures at present, but have both made early stage patient hand
After art treatment, still there are some patientss that will shift.Metastatic renal cell carcinoma prognosis is poor, insensitive to the treatment such as chemicotherapy, and 3 years flat
Equal survival rate is less than 5%.Therefore, it is current urgent problem to find new prognosis biomarker.
The development of sequencing technologies discloses, and many such conservative regions can be transcribed, and Transcriptional fragments are more than 200bp,
Containing polyA tails, open reading frame, referred to as long-chain non-coding RNA are free of, and was considered as once " transcription noise ".Closely
Long-chain non-coding RNA is proved to be widely present in multicellular animals over year, including mammal (such as mouse and the mankind), vertebra
Animal (such as chicken and zebra fish), arthropod (such as drosophila) or even nematode.Research finds the homologous sequence of long-chain non-coding RNA
Conservative is very low between species, but is found by calculating analysis, compared with ancestors' repetitive sequence in weakly acidic pH of evolving, people
Class, mouse and the long-chain of rat non-coding RNA homologous sequence receive the negative selection of bigger.Subsequent experimental study is gradually taken off
Show, long-chain non-coding RNA is most of all functional, the physiology courses such as many developments is participated in, by controlling encoding gene upstream
The transcription of promoter inhibits the chromatinic recombination of the activity of RNA polymerase, Jie's structure, the shearing of interference mRNA, is combined with protein
Changing the modes such as the positioning of protein in the cell influences the expression of gene, to participate in diversified pathology life in organism
Reason process.IFNG-AS1 is a kind of newfound non-coding RNA, and transcript length is more than 200 nucleotide.Currently,
The important function that IFNG-AS1 is played during normal cell development or tumor development is also in further research.
Whether IFNG-AS1 can be as a kind of new tumor markers for predicting that prognosis of patients with renal cell carcinoma not yet has been reported that.Therefore, I
Illustrate for the first time the feasibility of patient's prognosis predicted for new kidney marker with IFNG-AS1.
Invention content
The object of the present invention is to provide a kind of application of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1,
Secondly, the present invention provides a kind of detection marker non-coding RNA the IFNG-AS1 kit of expression quantity and inspection in renal carcinoma tissue
Survey method.
The object of the present invention is achieved like this：
Kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 is preparing answering for the preparation of prediction prognosis of patients with renal cell carcinoma
With the nucleic acid sequence such as SEQ NO of non-coding RNA IFNG-AS1:Shown in 1.
The preparation for predicting prognosis of patients with renal cell carcinoma is real-time fluorescence quantitative PCR detection kit.
Kit includes the specific primer for detecting non-coding RNA IFNG-AS1 expression, the specific primer
Nucleic acid sequence is SEQ NO:2 and SEQ NO:The primer sequence that 3 and reference gene TUBA1A is expressed, the nucleic acid of the primer
Sequence is SEQ NO:4 and SEQ NO:5.
Kit also contains all reagents for extracting RNA from tissue and carrying out reverse transcription and real-time fluorescence quantitative PCR, packet
Include (1) extracted total RNA agents useful for same from the tumour of kidney or normal control tissue, including Trizol liquid, chloroform, isopropanol,
Inhibit RNA degradations solvent, 75% ethyl alcohol, DEPC water；(2) it is by non-coding RNA IFNG-AS1 reverse transcriptions by template of total serum IgE
CDNA agents useful for same, including reverse transcription reaction buffer solution, contain triphosphoric acid base deoxynucleotide dNTP, reverse transcription containing Mg2+
The mixture of enzyme M-MLV and random primer and Oligo dT primers；(3) by cDNA real-time fluorescence quantitative PCR agents useful for same, packet
Include IFNG-AS1 real-time fluorescence quantitative PCRs specific primer, TUBA1A internal references Specific PCR primers, real time fluorescent quantitative SYBR
Dyestuff, the water without RNA enzyme.
The detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1, includes the following steps：1）It receives
Collect kidney to be measured or normal control tissue；
2) extracting of RNA in organizing；
3）The reverse transcription of IFNG-AS1 RNA, using cell total rna as template, reverse transcription obtains cDNA；
4）Using cDNA as template, real-time fluorescence quantitative PCR amplification is carried out using the specific primer of non-coding RNA IFNG-AS1,
Detect non-coding RNA IFNG-AS1 expression quantity.
Step 3）Middle reverse transcription reaction system is 5 × RT Buffer（Containing Mg2+ and dNTP）4 μ l, 10 × RT Primer
Mix（Oligo dT Primer and Random Hexamers mixtures）2 μ l, BeyoRT II M-MLV reverse transcriptases
(RNase H-)（Inhibitor containing RNase）2 μ l, DEPC-treated water, 2 μ l remove the Total RNA after gDNA
10μl。
Step 4）The expression quantity relative quantitation method of middle detection marker non-coding RNA IFNG-AS1.
The beneficial effects of the invention are as follows：Renal carcinoma tissue source is found by real-time fluorescence quantitative PCR and survivorship curve analysis
Non-coding RNA IFNG-AS1 it is related to the survival rate of patient, content is higher, and survival rate is higher, this method be prediction patients with renal cell carcinoma
Prognosis life cycle analysis provide strong technical support, help to improve the postoperative life quality of patients with renal cell carcinoma, work out
Aftertreatment scheme improves survival rate, has far-reaching clinical meaning.
Description of the drawings
Fig. 1 is that real-time fluorescence quantitative PCR analyzes differential expressions of the IFNG-AS1 in normal structure and kidney；
Prognosis of the non-coding RNA IFNG-AS1 expression height in the tracing analysis renal carcinoma tissue sources for survival Fig. 2 to patients with renal cell carcinoma
It influences.
Specific implementation mode
The present invention is made the following instructions with reference to embodiment：
Embodiment 1：Kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 is preparing prediction prognosis of patients with renal cell carcinoma
Marker non-coding RNA IFNG-AS1 is used to prepare the preparation of kidney prognosis, predicts the feelings of patients with renal cell carcinoma by the application of preparation
Condition.
Embodiment 2：The reagent for preparing detection non-coding RNA IFNG-AS1 expression quantity is used to prepare prognosis of patients with renal cell carcinoma
Kit (being used for 30 secondary responses) 1. Trizo l20ml
2. inhibiting RNA degradation solvents 40ml；
3. chloroform 80ml；
4. isopropanol 80ml；
5. DEPC water 10ml；
6. the 100 μ l of mixture of 10 × random primer and Oligo dT primers；
7. 5 × reverse transcription reaction buffer solution, 150 μ l；
8. triphosphoric acid base deoxynucleotide dNTP 100 μ ls of the 10mM containing Mg2+；
9. 50 μ l of 200U/ μ l M-MLV reverse transcriptases；
10. SYBR Green qPCR Mix 500μl；
11. 3 μM of target gene IFNG-AS1 specific primers（Its sequence such as SEQ NO:2 and SEQ NO:Shown in 3） 50μl；
12. 3 μM of reference gene TUBA1A specific primers（Its sequence such as SEQ NO:4 and SEQ NO:Shown in 5） 50μl.
Embodiment 3：The detection of tissue samples non-coding RNA IFNG-AS1
1, kidney to be measured or normal control tissue are collected, after physiological saline cleans up, is put into and fills inhibition RNA degradation solvents
In cryopreservation tube, put spare to -80 DEG C of refrigerators.
2, the extracting of RNA in organizing：
（1）Liquid nitrogen is first added in mortar, then tissue is cut into small pieces and is clayed into power in liquid nitrogen, is taken with the spoon of Liquid nitrogen precooler
100mg organizes powder to be added in the EP pipes for the Trizol liquid for having filled 1ml.Organize total powder volume no more than Trizol used
The 10% of volume is sufficiently mixed uniformly；
（2）5 minutes are placed at room temperature for, the chloroform of 200 μ L is then added, EP is covered tightly and manages and acutely sway 0.5 minute.12000 revs/min
Zhongli's heart 10 minutes；
（3）Take upper strata aqueous phase in a new EP pipes（The intermediate beds of precipitation and subnatant are not mixed into）, 500 μ L isopropanols are added,
Mildly reverse mixing, is placed at room temperature for 10 minutes, and 12000 revs/min centrifuge 10 minutes.
（4）Liquid is carefully discarded supernatant, is added 75% ethyl alcohol of 1ml, vortex mixing, 12000 revs/min of centrifugations 5 at 4 DEG C
Minute, repetitive operation is primary；
（5）Discard supernatant liquid（Residual liquid is removed as possible）, room temperature or vacuum drying 5~10 minutes（It is careful not to dried
Point, it otherwise can reduce the solubility of RNA）, RNA is dissolved with 50 μ L DEPC processed water；
（6）RNA concentration mensurations：It is measured with nucleic acid concentration analyzer, inhales 1 μ L RNA samples and add to sample well, according to reading
Directly determine the concentration of RNA.The OD260/OD280 ratios of the measurement of nucleic acid concentration analyzer, ratio are thought between 1.8-2.0
RNA purity is fine, and finally, it is spare that RNA is stored in -80 DEG C of refrigerators.
3, the reverse transcription of IFNG-AS1 RNA：Use the Reverse Transcriptase kit of the green skies Bioisystech Co., Ltd in Shanghai
（D7170S）, it is as follows：
（1）Remove genomic DNA：Template Total RNA, 5 × gDNA Eraser Buffer are thawed on ice, 5 × RT
Buffer, 10 × RT Primer Mix, DEPC-treated Water are immediately placed in (15-25 DEG C) defrosting of room temperature after defrosting
On ice.Using it is preceding by each solution mixing and it is of short duration centrifugation so that all liq is settled down to tube bottom.The denaturation of RNA, RNA samples
Product thermal denaturation under the conditions of 65 DEG C is immediately placed in ice water cooling after 5 minutes.According to the form below ingredient is in the mixing of preparation reaction on ice
Then liquid is dispensed into each reaction tube, is eventually adding RNA sample again；
（2）In PCR instrument or in water-bath, 37 DEG C are incubated 2 minutes.Be immediately placed in place on ice it is spare；（3）Reverse transcription system is matched
System：Reaction solution preparation is carried out on ice, and reverse transcription reaction is carried out immediately after soft mixing.According to the reverse transcription reaction system of following table
Prepare mixed liquor；
（4）42 DEG C are incubated 60 minutes to carry out reverse transcription reaction, and subsequent 80 DEG C of incubations are put in for 10 minutes after inactivation reverse transcriptase
On ice, for the template of secondary structure complexity or high GC content, reverse transcription temperature can be improved to 50 DEG C, to enhance reverse transcription effect
Rate；（5）Obtained cDNA can immediately or -80 DEG C freeze after be used for follow-up real-time fluorescence quantitative PCR, cDNA preferably avoids excessive
Multigelation.
4, real-time fluorescence quantitative PCR is carried out using the specific primer of non-coding RNA IFNG-AS1：Specific primer exists
Raw work bioengineering（Shanghai）Limited liability company synthesizes, and includes the specificity for detecting non-coding RNA IFNG-AS1 expression
Primer, primer sequence are SEQ NO:2 and SEQ NO:The primer sequence that 3 and reference gene TUBA1A is expressed, primer sequence are
SEQ NO:4 and SEQ NO:5.The other reagents of real-time fluorescence quantitative PCR utilize the green skies Bioisystech Co., Ltd in Shanghai
BeyoFast SYBR Green qPCR Mix (2 ×), are as follows：
（1）Melt and mixing PCR reacts required various solution, BeyoFast SYBR Green qPCR Mix melt completely
And mixing is placed in ice chest；（2）PCR reaction systems (by taking 96 orifice plates as an example) are set on ice bath：
(3) the usually amount of DNA profiling with 1-10ng cDNA is with reference to dosage, and final concentration of 0.2-0.5 μM of primer when can be obtained
Good detection result is obtained, the final concentration of primer also can be according to circumstances adjusted.If it is necessary, gradient dilution can be carried out to template,
With the template usage amount that determination is best.When reverse transcription PCR cDNA obtained by the reaction is directly as template, additive amount does not exceed
PCR reacts the 10% of total volume.The recommendation response system of 96 orifice plates is 20 μ l, can also in proportion be expanded according to actual experiment demand
Big or diminution reaction system；
(4) mixing or slight Vortex mixings are gently blown and beaten with pipettor, room temperature centrifuges the several seconds, liquid is made to accumulate in tube bottom；
(5) the PCR reaction tubes set or PCR reaction plates are placed on fluorescence quantitative PCR instrument, start PCR reactions；(6) PCR reacts
Program：The pre-degeneration that template is carried out before real-time fluorescence quantitative PCR reacts, is typically set at 95 DEG C 2 minutes.Using following
PCR programs, this program are by taking ABI 7900HT fluorescence quantitative PCR instruments as an example：A. pre-degeneration：95℃ 2min ；B. it is denaturalized：
95℃ 15sec；C. annealing/extension：60℃ 15-30sec；D. step b and step c is repeated, in total 40 cycles； e.
Melting curve analysis (optional)：95℃ 15sec, 60℃ 15sec, 95℃ 15sec；F. it is carried using fluorescence quantitative PCR instrument
The software analysis result of confession；Three-step approach need to only add 72 DEG C of 30sec of a step after annealing/extension, then repeat step b, c and increasing
Add the step for totally 40 cycle.
5, the data analysis of non-coding RNA IFNG-AS1 expression quantity：This experimental data is included in 60 patients with renal cell carcinoma and its just
Normal control tissue.The interpretation of result of real-time quantitative PCR uses relative quantitation method, that is, 2^- △ △ Ct methods.It is specific as follows：First,
All gene C t values once tested are put in order, later with the Ct values of the target gene IFNG-AS1 in each group of tumor sample
The Ct values of itself reference gene TUBA1A are subtracted, obtained number is exactly △ Ct；Changing formula into is exactly：△Ct=Ct（Target gene
IFNG-AS1）-Ct（Reference gene TUBA1A）；Then, by the △ of each group of each target gene of tumor sample IFNG-AS1
Ct is calculated.The △ Ct of normal control tissue group sample are subtracted with the △ Ct of tumor tissues sample in this experiment, and right simultaneously
All results take opposite number, and the result which obtains is exactly-△ △ Ct.Finally, p- △ △ Ct carry out 2 power operation, i.e.,
2^- △ △ Ct just show that the multiple of expression quantity changes.In triplicate, it is examined using nonparametric t- for statistical analysis.We send out
Existing, the expression quantity of IFNG-AS1 is higher than normal control in the tumor tissues of kidney（See Fig. 1）, difference is with significant difference (p ＜
0.05)。
6, by 60 patients with renal cell carcinoma follow-up statistics being included in above-mentioned experiment, including patient's First episode when
Between, treatment, recurrence status and death time etc., follow up time is at least 12 months.In selected patients with renal cell carcinoma, choosing
It is reference standard to take the expression value that real-time fluorescence quantitative PCR is analyzed, and the corresponding normal structure of acquired results compares.Tumour
Non-coding RNA IFNG-AS1 expression is defined as non-coding RNA IFNG-AS1 high higher than the patient of normal control tissue in tissue
Expression group, remaining is low expression group.By Kaplan-Meier survival analysis, non-coding RNA IFNG-AS1 high expresses patient's
Life cycle is substantially reduced than the patient of non-coding RNA IFNG-AS1 low expression groups, and prognosis is worse（See Fig. 2）, difference has system
Meter learns meaning (p ＜ 0.05).Therefore, non-coding RNA IFNG-AS1 can be used as the specific molecular markers of prognosis of patients with renal cell carcinoma
Object.
Sequence table
<110>The first affiliated hospital of Zhengzhou University
<120>Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1
<141> 2018-04-27
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1131
<212> DNA
<213> Homo sapiens
<400> 1
ccttgcccac cttctgcaca ccaagcgtgg attctgcaaa acgtgagccc aacaggaagc 60
tgcctgcaat ttcaggtagc ttttctgact cttaaagaga tctcaagtat accttcagag 120
aaatgccagc aaaaactgta gtcatttggg aaggaataag cctggaagaa aaagatacaa 180
cgaactagca caacgaggag tttgaaaagt tcatgacagc tcacagctga tgatggtggc 240
aatcttaagg atacagaaag ctcattcctc atgcagggaa gaagaaaata ttctaaagaa 300
gagataagca tattccatga aatcaaaaaa ggtaggaaaa caatatttat tcattaactc 360
cttcactcac tcaacgaaca tatatttagt gcctactatg tgttaggcat ggtaccagaa 420
tctggaatcc aaaatttaaa aagtctctgt cctgaagagt ttacaagaca gggcagtaag 480
taagtgatca aaataccgta tgatagcaat tagtacaagg catggagctg agcctggata 540
gtaaagcaga ggccatgtga atgagttttg tctttattct gatacaaatg tgaatccatt 600
gaaagattta aacaaagaga atgccatcta actagtttca ttcttaaaag atcatacttg 660
ttgtatagtg agaacaaatt gaatggtgaa tcagagctga gattttgtta tttttataac 720
tacaaaatct tgtatagttt tctacaccta taaagtacaa tgagttcaca ccctcttaaa 780
tctatgtagc tgtgtgtccc tccatgctat tattcatcta gcagtctgcc ttctgctccc 840
actcatttcc ctacaatgag taacagaact gcaagtagac aaagaaggat ggagaatgaa 900
cttggcttct ctctttcaaa tggaagctag cagaaaagct caggaactca caccttgagg 960
agagggtaat atgcagtggt taataacata ggatattgat ttaaaaacca gtgttgtcca 1020
ttgctcattc tatgacctta ggcaaacttg tcaatatttc tgctcttaat atctttactt 1080
tatgatggta ataaagttat ttctatcttt tatttgtcag actcagctaa c 1131
<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 2
caaaacgtga gcccaacagg 20
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 3
actatccagg ctcagctcca 20
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 4
caactaccag cctcccactg 20
<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence
<400> 5
cagtgggagg ctggtagttg 20
Claims (7)
1. kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 is preparing the preparation of prediction prognosis of patients with renal cell carcinoma
Using the nucleic acid sequence such as SEQ NO of non-coding RNA IFNG-AS1:Shown in 1.
2. the application of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 according to claim 1, special
Sign is：The preparation for predicting prognosis of patients with renal cell carcinoma is real-time fluorescence quantitative PCR detection kit.
3. a kind of kit as claimed in claim 2, it is characterised in that：Including being used to detect non-coding RNA IFNG-AS1 tables
The nucleic acid sequence of the specific primer reached, the specific primer is SEQ NO:2 and SEQ NO:3 and reference gene
The nucleic acid sequence of the primer sequence of TUBA1A expression, the primer is SEQ NO:4 and SEQ NO:5.
4. kit according to claim 3, it is characterised in that：Also contain and extracts RNA from tissue and carry out reverse transcription
And all reagents of real-time fluorescence quantitative PCR, including (1) from the tumour of kidney or normal control tissue used in extracted total RNA
Reagent, including Trizol liquid, chloroform, isopropanol, inhibition RNA degradations solvent, 75% ethyl alcohol, DEPC water；(2) using total serum IgE as mould
Non-coding RNA IFNG-AS1 reverse transcriptions are cDNA agents useful for same by plate, including reverse transcription reaction buffer solution, contain three containing Mg2+
The mixture of phosphoric acid base deoxynucleotide dNTP, reverse transcriptase M-MLV and random primer and Oligo dT primers；(3) will
CDNA real-time fluorescence quantitative PCR agents useful for same, including IFNG-AS1 real-time fluorescence quantitative PCRs specific primer, TUBA1A internal references
Specific PCR primers, real time fluorescent quantitative SYBR dyestuffs, the water without RNA enzyme.
5. the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1, it is characterised in that：Including following
Step：1）Collect kidney to be measured or normal control tissue；
2) extracting of RNA in organizing；
3）The reverse transcription of IFNG-AS1 RNA, using cell total rna as template, reverse transcription obtains cDNA；
4）Using cDNA as template, real-time fluorescence quantitative PCR amplification is carried out using the specific primer of non-coding RNA IFNG-AS1,
Detect non-coding RNA IFNG-AS1 expression quantity.
6. the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 according to claim 5,
It is characterized in that：Step 3）Middle reverse transcription reaction system is 5 × RT Buffer（Containing Mg2+ and dNTP）4 μ l, 10 × RT Primer
Mix（Oligo dT Primer and Random Hexamers mixtures）2 μ l, BeyoRT II M-MLV reverse transcriptases
(RNase H-)（Inhibitor containing RNase）2 μ l, DEPC-treated water, 2 μ l remove the Total RNA after gDNA
10μl。
7. the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 according to claim 5,
It is characterized in that：Step 4）The expression quantity relative quantitation method of middle detection marker non-coding RNA IFNG-AS1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810742140.4A CN108531606A (en) | 2018-07-09 | 2018-07-09 | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810742140.4A CN108531606A (en) | 2018-07-09 | 2018-07-09 | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108531606A true CN108531606A (en) | 2018-09-14 |
Family
ID=63487777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810742140.4A Withdrawn CN108531606A (en) | 2018-07-09 | 2018-07-09 | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108531606A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107488726A (en) * | 2017-09-25 | 2017-12-19 | 中国人民解放军南京军区南京总医院 | A kind of kidney prognosis evaluation biomarker and its detection reagent and application |
-
2018
- 2018-07-09 CN CN201810742140.4A patent/CN108531606A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107488726A (en) * | 2017-09-25 | 2017-12-19 | 中国人民解放军南京军区南京总医院 | A kind of kidney prognosis evaluation biomarker and its detection reagent and application |
Non-Patent Citations (2)
| Title |
|---|
| TONG LIU 等: "Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma", 《ONCOL REP》 * |
| 陈健文等: "长链非编码RNA及其在肾癌中的研究进展", 《微创泌尿外科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101940657B1 (en) | System for predicting prognosis and group classification based on gastric cancer reveal subtype-associated biological implication | |
| IL272226A (en) | Diagnostic, prognostic and therapeutic uses of long noncoding rnas for heart disease and regenerative medicine | |
| CN109182521B (en) | Application of circRNA as thyroid papillary carcinoma marker | |
| WO2011079846A2 (en) | Mrna classification of thyroid follicular neoplasia | |
| CA2877864A1 (en) | Targeted rna-seq methods and materials for the diagnosis of prostate cancer | |
| CN108893541B (en) | Porcine subcutaneous fat-related circular RNA and application thereof | |
| CN107519193B (en) | Molecular diagnostic marker for early stage esophageal squamous carcinoma and application thereof | |
| CN108893540A (en) | It circRNA_14707 and its is applied in marker assisted selection | |
| CN111118170B (en) | Application of chi-miR-450-5p as goat follicle maturation miRNA marker | |
| CN108707664A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-COX19-2 and its application | |
| CN108728547A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00158 | |
| CA2851752A1 (en) | Method for quantifying renal markers by urinary dosage | |
| CN108424965A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CRYBA4-23 and its application | |
| CN108531606A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 | |
| CN108753960A (en) | A kind of gastric cancer prognosis molecule marker non-coding RNA Lnc-DENR-2 and its application | |
| CN108546760A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-COL20A1-2 and its application | |
| CN108753978A (en) | Application, kit and the detection method of lung cancer for prognosis novel molecular marker non-coding RNA LINC01124 | |
| CN108424966A (en) | A kind of gastric cancer prognosis molecule marker non-coding RNA Lnc-CIT-1 and its application | |
| CN109266742A (en) | Predict the biomarker long-chain non-coding RNA LINC02456 and kit of colon cancer prognosis | |
| CN108753977A (en) | Application, kit and the detection method of lung cancer for prognosis novel molecular marker non-coding RNA LINC00958 | |
| Liu et al. | Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia | |
| CN108998519A (en) | Predict the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis | |
| CN108796087A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00668 | |
| CN108977536A (en) | Predict the biomarker long-chain non-coding RNA LINC01504 and kit of lung cancer for prognosis | |
| CN108642184A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00200 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180914 |
|
| WW01 | Invention patent application withdrawn after publication |